Mainz Biomed N.V. (MYNZ)

NASDAQ: MYNZ · Real-Time Price · USD
3.580
-0.388 (-9.78%)
At close: Mar 28, 2025, 4:00 PM
3.829
+0.249 (6.94%)
After-hours: Mar 28, 2025, 7:13 PM EDT
-9.78%
Market Cap 12.06M
Revenue (ttm) 917,203
Net Income (ttm) -22.51M
Shares Out 3.37M
EPS (ttm) -44.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 263,338
Open 3.920
Previous Close 3.968
Day's Range 3.290 - 3.980
52-Week Range 0.180 - 8.200
Beta 0.33
Analysts Buy
Price Target 14.00 (+291.06%)
Earnings Date Apr 15, 2025

About MYNZ

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany. [Read more]

Sector Healthcare
IPO Date Nov 5, 2021
Employees 71
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Full Company Profile

Financial Performance

In 2023, Mainz Biomed's revenue was $895,479, an increase of 69.00% compared to the previous year's $529,877. Losses were -$26.30 million, -0.35% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 291.06% from the latest price.

Price Target
$14.0
(291.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report To...

1 day ago - GlobeNewsWire

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement...

15 days ago - GlobeNewsWire

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) --  Mainz Biomed N.V.

25 days ago - GlobeNewsWire

Mainz Biomed Expands into Switzerland with labor team w

BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

5 weeks ago - GlobeNewsWire

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

6 weeks ago - GlobeNewsWire

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

2 months ago - GlobeNewsWire

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the s...

2 months ago - GlobeNewsWire

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

3 months ago - GlobeNewsWire

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

3 months ago - GlobeNewsWire

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

3 months ago - GlobeNewsWire

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.

Other symbols: TMO
4 months ago - Benzinga

Mainz Biomed Announces Stock Split

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

4 months ago - GlobeNewsWire

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensiti...

5 months ago - GlobeNewsWire

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert

6 months ago - GlobeNewsWire

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

6 months ago - GlobeNewsWire

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

BERKELEY, Calif. and MAINZ, Germany, Sept.

6 months ago - GlobeNewsWire

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

8 months ago - GlobeNewsWire

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration st...

9 months ago - GlobeNewsWire

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

9 months ago - GlobeNewsWire

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Result...

10 months ago - GlobeNewsWire

Mainz Biomed Reports Results of 2024 Annual General Meeting

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

10 months ago - GlobeNewsWire

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported sampl...

10 months ago - GlobeNewsWire

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancero...

11 months ago - GlobeNewsWire

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

11 months ago - GlobeNewsWire